Ars Live recap: When are the big rockets NASA desperately needs going to be ready?

The New Glenn rocket explosion in late May is raising near-term execution risk for NASA’s Artemis IV human Moon-landing timeline. Blue Origin’s reported human-mission “architecture” would require four launches of the new 9x4 New Glenn variant (nine first-stage engines and four upper-stage engines), with a potential debut targeted for late 2027/early 2028. The failure also heightens dependency on competitor lander efforts from both Blue Origin and SpaceX to keep Artemis plans on track.

Analysis

The main market mechanism is not a launch failure headline; it is a credibility tax on any program that depends on multi-launch coordination and unproven heavy-lift cadence. That tends to widen the gap between “flight heritage” names and ambitious but still liquidity-dependent space stories, because customers and government buyers pay up for schedule certainty, not just payload specs. In the public market, RKLB is the cleanest beneficiary if capital rotates toward operational execution over aspirational timelines.

For NASA-adjacent primes, the near-term effect is mixed: a slip in one provider can concentrate work with the most reliable counterparties, but it also raises the odds that Artemis milestones drift right and budget pressure shifts from Moon-specific spending to broader defense and space infrastructure priorities. That favors large balance-sheet names with diversified backlog, like LMT and NOC, over single-theme space exposure. Insurance, launch services, and supplier margins should also face modest upward pressure if customers demand more redundancy and test flights.

The contrarian view is that the stock market may underprice the second-order benefit to SpaceX-like incumbency and overprice the “space sector is broken” narrative. A failure by one private player can actually strengthen the moat of whoever can demonstrate repeated success, and the public comps that look expensive on current revenue can de-risk faster than the market expects. The key falsifier is a rapid, credible recovery path: if Blue Origin/partners show a successful heavy-lift test cadence within 2-3 quarters, the reliability premium should fade quickly.

Key Decisions for Investors

• Long RKLB on weakness versus ARKX for a 1-3 month relative-value trade; thesis is that reliability/flight cadence becomes the dominant valuation factor after a high-profile setback. Stop if RKLB underperforms ARKX by >8% on no company-specific weakness.
• Add LMT/NOC on a 3-6 month horizon as a defensive way to express Artemis schedule slippage risk; these names should absorb any reallocation toward broader defense and space infrastructure budgets. Falsify if NASA messaging keeps the lunar timeline intact and suppliers see no program deferrals.
• Avoid chasing pre-revenue space names until there is evidence of repeated successful heavy-lift testing; the financing risk is the real second-order loser here. Reassess if launch insurance pricing or customer deposits indicate no tightening.
• Watch for any successful 9x4 test or firm Artemis timetable update over the next 1-2 quarters; that would unwind the reliability premium and pressure the long-RKLB / long-LMT-NOC relative thesis.